Vaccine stocks

Ticker
Name
Market cap, $
Price, $
Price change, %01 Nov 2024
Type
Country
PE ratio
PB ratio
PS ratio
Revenue (quarterly), $
EPS diluted (quarterly), $
Johnson & Johnson385.73 B160.21+0.27StockUnited States26.485.504.4022.47 B1.11
Merck & Co258.40 B101.94-0.08StockUnited States18.915.934.1416.11 B2.14
AstraZeneca226.34 B73.00+2.80StockUnited Kingdom35.275.734.6112.94 B0.62
Pfizer159.35 B28.12-0.85StockUnited States38.002.6517.70 B0.78
GSK75.31 B36.91+0.30StockUnited Kingdom24.004.021.9010.43 B-0.04
BioNTech SE26.61 B111.90+0.54StockGermany1.309.14138.58 M-3.62
Moderna21.05 B54.76+1.15StockUnited States1.804.22221.00 M-3.33
Dynavax Technologies1.54 B11.78+0.68StockUnited States107.092.406.1873.80 M0.08
Novavax1.50 B9.37-2.90StockUnited States-3.471.91415.48 M0.99
Phreesia1.09 B18.79+4.68StockUnited States4.322.78102.11 M-0.31
Ocugen268.40 M0.93+0.26StockUnited States15.8632.771.14 M-0.04
Vaxart172.83 M0.76-1.31StockUnited States2.1611.046.40 M-0.09
On page:
On page:
Total: 12

Charts

Earnings and dividend calendar

Vaccine stocks news

Astrazeneca (AZN) Rises But Trails Market: What Investors Should Know
zacks.com01 November 2024 Sentiment: POSITIVE

In the most recent trading session, Astrazeneca (AZN) closed at $71.42, indicating a +0.38% shift from the previous trading day.

Merck's Gardasil Shot Challenges To Continue, Analysts Optimistic For Newly Approved Sotatercept For Rare Lung Disease
benzinga.com01 November 2024 Sentiment: POSITIVE

On Thursday, Merck & Co Inc MRK announced that its sales for the third quarter reached $16.66 billion, which is a 4% increase compared to the same period last year. This figure surpassed the expected amount of $16.47 billion.

Baby Boomers: 2 Super-High-Yield Stocks to Watch in November
247wallst.com01 November 2024 Sentiment: POSITIVE

Baby Boomer investors who are dissatisfied with the decreasing interest rates on their savings and CDs might find dividend stocks appealing at this time.

Is Merck Stock a Buy?
fool.com01 November 2024 Sentiment: POSITIVE

The upcoming years could be challenging for the big pharmaceutical company, but the future seems more promising.

Phreesia Sets Release Date for Fiscal Third Quarter 2025 Results
businesswire.com01 November 2024 Sentiment: NEUTRAL

ALL-REMOTE COMPANY/WILMINGTON, Del.--(BUSINESS WIRE)--Phreesia announced that it will release its fiscal third quarter 2025 financial results after the close of market trading on Monday, Dec. 9, 2024.

ATTENTION NVAX SHAREHOLDERS: Investors Who Lost Money on Novavax, Inc. are Urged to Contact Levi & Korsinsky about an Ongoing Investigation
accesswire.com31 October 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / October 31, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Novavax, Inc. ("Novavax, Inc.") (NASDAQ:NVAX) concerning possible violations of federal securities laws. On October 16, 2024, NVAX announced the Food and Drug Administration placed a clinical hold on the development of the company's combination influenza and Covid-19 (CIC) shot and its stand-alone influenza vaccine.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novavax, Inc. - NVAX
accesswire.com31 October 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / October 31, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Novavax, Inc. ("Novavax" or the "Company") (NASDAQ:NVAX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Merck & Co., Inc. (MRK) Q3 2024 Earnings Conference Call Transcript
seekingalpha.com31 October 2024 Sentiment: POSITIVE

The Merck & Co., Inc. Q3 2024 Earnings Call is scheduled for October 31, 2024, at 09:00 AM ET. Key company participants include Peter Dannenbaum, Rob Davis, Caroline Litchfield, and Dean Li. Various conference call participants from different financial institutions will also be present.

Pfizer: Overstated Pessimism Makes Little Sense
seekingalpha.com31 October 2024 Sentiment: POSITIVE

Pfizer exceeded expectations for both revenue and adjusted earnings per share, thanks to the unexpected success of its COVID-related products. However, the mixed reaction after the earnings report indicates that Pfizer must focus on its growth opportunities outside of COVID. It seems that PFE has likely moved beyond its lowest points from early 2024, showing that the market believes the toughest times are behind it.

Pfizer CEO on Q3 earnings, exceptional with phenomenal growth
youtube.com31 October 2024 Sentiment: POSITIVE

After Pfizer (PFE) reported better-than-expected earnings for the third quarter and increased its full-year forecast, CEO Albert Bourla appeared on Market Domination to talk about the "remarkable quarter." He highlighted that both Pfizer's earnings and revenue, as well as its COVID and non-COVID sectors, exceeded expectations.